Aroa Biosurgery Balance Sheet Health
Financial Health criteria checks 6/6
Aroa Biosurgery has a total shareholder equity of NZ$92.4M and total debt of NZ$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NZ$108.7M and NZ$16.4M respectively. Aroa Biosurgery's EBIT is NZ$630.0K making its interest coverage ratio -1.9. It has cash and short-term investments of NZ$23.6M.
Key information
0%
Debt to equity ratio
NZ$0
Debt
| Interest coverage ratio | -1.9x |
| Cash | NZ$23.64m |
| Equity | NZ$92.37m |
| Total liabilities | NZ$16.37m |
| Total assets | NZ$108.74m |
Recent financial health updates
Aroa Biosurgery (ASX:ARX) Is In A Strong Position To Grow Its Business
Mar 24
We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn
Nov 13Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation
Mar 25We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth
May 13Recent updates
Aroa Biosurgery Limited (ASX:ARX) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 28
Lebanon, Vietnam, And Saudi Arabia Approvals Will Secure Market Presence
Expansion into international markets and positive clinical outcomes suggest potential revenue growth as new regions adopt Aroa's cost-effective products.Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Apr 07Aroa Biosurgery (ASX:ARX) Is In A Strong Position To Grow Its Business
Mar 24Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Feb 15Aroa Biosurgery Limited (ASX:ARX) Held Back By Insufficient Growth Even After Shares Climb 26%
Dec 04The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts
Nov 27We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn
Nov 13Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper
Aug 22Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues
Jun 12Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation
Mar 25Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge
Jan 30Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors
Nov 14Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts
Nov 02Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price
Oct 25We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth
May 13Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results
May 26An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued
Mar 22Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?
Feb 24Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)
Feb 24Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price
Dec 16
Financial Position Analysis
Short Term Liabilities: ARX's short term assets (NZ$68.0M) exceed its short term liabilities (NZ$10.4M).
Long Term Liabilities: ARX's short term assets (NZ$68.0M) exceed its long term liabilities (NZ$5.9M).
Debt to Equity History and Analysis
Debt Level: ARX is debt free.
Reducing Debt: ARX has no debt compared to 5 years ago when its debt to equity ratio was 16%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ARX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ARX is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 1.1% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 05:20 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aroa Biosurgery Limited is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Elyse Shapiro | Canaccord Genuity |
| Steven Wheen | Jarden Limited |